Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira (PCRX) delivered earnings and revenue surprises of 9.09% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Beats Q3 Earnings Estimates

-- Third quarter GAAP net income of $17.7 million and adjusted EBITDA of $48.1 million -- -- Conference call today at 8:30 a.m. ET --

Pacira BioSciences Reports Third Quarter 2021 Financial Results

-- Patent eligible for Orange Book listing will provide additional protection into 2041 -- TAMPA, Fla., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a U.S. Patent Application claiming chemical composition of EXPAREL® (bupivacaine liposome injectable suspension). After issuance, Pacira will submit this patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Patents that are eligible for Orange Book listing are those that have claims covering the active ingredient, the drug product (formulation and composition) or the approved method of use.

Pacira Receives Notice of Allowance for New Patent Covering EXPAREL Composition

PARSIPPANY, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday, November 3, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report Third Quarter 2021 Financial Results on Wednesday November 3, 2021

Flexion Therapeutics

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition of the Company by Pacira BioSciences, Inc. ("Pacira") (NASDAQ: PCRX).  Under the terms of the merger agreement, Pacira will commence a tender offer to acquire all outstanding shares of Flexion for a purchase price of $8.50 per share in cash, plus one non-tradeable contingent value right ("CVR").

SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Flexion Therapeutics, Inc.

FLXN stock is surging upward today as the company announces a merger with fellow biopharma play Pacira, valuing the company at $450 million. The post FLXN Stock Is Winning Big Today Ahead of Merger With Pacira appeared first on InvestorPlace.

FLXN Stock Is Winning Big Today Ahead of Merger With Pacira

Pacira BioSciences Inc (NASDAQ: PCRX) has agreed to acquire Flexion Therapeutics Inc (NASDAQ: FLXN) for $8.50 per share in cash, plus one contingent value right (CVR) worth up to $8.00 per share in cash.  Pacira ended Q2 of 2021 with cash, cash equivalents, and short-term investments of $646.6 million.

Pacira Beefs Up Non-Opioid Pain Management Via Flexion Acquisition

Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.

Flexion Therapeutics shares soar 39% premarket on news to be acquired by Pacira Biosciences

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

TAMPA, Fla., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it will host an Investor Day on Friday, October 15, 2021, from 8:00 AM to approximately 12:00 PM ET. Key Opinion Leaders and members of the Pacira executive team will provide updates on the Company's commercial products and pipeline opportunities. The event is taking place at The Pacira Innovation and Training Center at Tampa (the PITT). In-person attendance requires advance registration and is subject to space limitations.

Pacira BioSciences to Host Investor Day on October 15th, 2021 in Tampa, FL

Pacira (PCRX) receives a Paragraph IV Certification notice letter notifying that eVenus has submitted an ANDA for marketing a generic version of Exparel in the United States.

Pacira (PCRX) Gets Notification of ANDA for Exparel, Stock Down

A potential rival hopes to win FDA approval of a generic version of Pacira's top-selling pain drug.

Why Pacira Biosciences Stock Sank Today

TAMPA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has received a Paragraph IV Certification Notice Letter advising that eVenus Pharmaceutical Laboratories, Inc. of Princeton, New Jersey, submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization for the manufacturing and marketing of a generic version of EXPAREL® (bupivacaine liposome injectable suspension) in the United States.

Pacira BioSciences Notified of Abbreviated New Drug Application Filing for EXPAREL®

Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024 Marks key step in achieving EXPAREL gross margins that exceed 85 percent by 2024

Pacira Announces Commercial Production Underway with Enhanced EXPAREL Manufacturing Process at Swindon Facility

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmuneID appoints veteran biotech executive James S. Scibetta as Chief Executive Officer.

ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO

Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

You should want to know, because knowing when to put the gain in your wallet to be reinvested in the next one has very few better strategies.

Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- -- More than nine million patients treated with EXPAREL as of August 2021 --

Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021

PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound?

-- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 -- -- EXPAREL momentum continues with July 2021 average daily sales at 117% of July 2020 --

Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 Million for July 2021

Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.

Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q2 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 1.32% and -0.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Pacira Pharmaceuticals Stock (PCRX)